SECTOR GAMMA AS
13F Reported Value
ⓘ$423.5M
Holdings
42
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
SECTOR GAMMA AS disclosed 42 positions worth $423.5M in its Form 13F-HR for Q1 2026, led by $BMY (BRISTOL MYERS SQUIBB CO) at 11.9% of the equity portfolio, followed by $MRK and $PFE. During the quarter the fund opened 11 new positions and exited 5 — including a new stake in $UNH and a full exit from $TMO. The portfolio is most concentrated in Healthcare (92.2% of disclosed assets). All figures are sourced directly from SECTOR GAMMA AS’s Form 13F-HR filing with the SEC under CIK 1475373.
AI Fund Analysis
DiversifyingSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
- 70.1#330
Quality
$50.2M827,901 sh - 70.9#284
Quality
$31.3M260,340 sh - 69.0#389
Quality
$30.6M1,091,385 sh - —
Quality
$24.3M280,682 sh - 81.2
Quality
$18.9M200,510 sh - 79.5
Quality
$16.6M47,155 sh - 65.6
Quality
$16.5M90,096 sh - 64.9
Quality
$14.1M155,835 sh - 74.1
Quality
$13.6M239,918 sh - 50.7
Quality
$13.0M82,615 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 BRISTOL MYERS SQUIBB CO$BMY | 70.1#330 | $50.2M | 827,901 |
 Merck & Co., Inc.$MRK | 70.9#284 | $31.3M | 260,340 |
 PFIZER INC$PFE | 69.0#389 | $30.6M | 1,091,385 |
 Medtronic plc$MDT | — | $24.3M | 280,682 |
 INCYTE CORP$INCY | 81.2 | $18.9M | 200,510 |
 AMGEN INC$AMGN | 79.5 | $16.6M | 47,155 |
 BIOGEN INC.$BIIB | 65.6 | $16.5M | 90,096 |
 ZIMMER BIOMET HOLDINGS, INC.$ZBH | 64.9 | $14.1M | 155,835 |
 BIOMARIN PHARMACEUTICAL INC$BMRN | 74.1 | $13.6M | 239,918 |
 BECTON DICKINSON & CO$BDX | 50.7 | $13.0M | 82,615 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of SECTOR GAMMA AS's 42 positions.
Showing top 10 of 42 holdings.
Sector Allocation
Healthcare
$390.6M
Technology
$21.2M
Consumer Staples
$11.6M
Full Holdings — SECTOR GAMMA AS (Q1 2026)
All 42 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $BMY | BRISTOL MYERS SQUIBB CO | $50.2M | 11.9% | +11% | 70.1 |
| 2 | $MRK | Merck & Co., Inc. | $31.3M | 7.4% | -28% | 70.9 |
| 3 | $PFE | PFIZER INC | $30.6M | 7.2% | +27% | 69 |
| 4 | $MDT | Medtronic plc | $24.3M | 5.7% | +4% | — |
| 5 | $INCY | INCYTE CORP | $18.9M | 4.5% | -8% | 81.2 |
| 6 | $AMGN | AMGEN INC | $16.6M | 3.9% | -23% | 79.5 |
| 7 | $BIIB | BIOGEN INC. | $16.5M | 3.9% | +5% | 65.6 |
| 8 | $ZBH | ZIMMER BIOMET HOLDINGS, INC. | $14.1M | 3.3% | +18% | 64.9 |
| 9 | $BMRN | BIOMARIN PHARMACEUTICAL INC | $13.6M | 3.2% | +21% | 74.1 |
| 10 | $BDX | BECTON DICKINSON & CO | $13.0M | 3.1% | -38% | 50.7 |
| 11 |  $ELV | Elevance Health, Inc. | $12.9M | 3.0% | +35% | 59.4 |
| 12 |  $IONS | IONIS PHARMACEUTICALS INC | $12.7M | 3.0% | -8% | 37.1 |
| 13 |  $CAH | CARDINAL HEALTH INC | $11.6M | 2.7% | -11% | 58.6 |
| 14 |  $UNH | UNITEDHEALTH GROUP INC | $9.9M | 2.3% | NEW | 66.8 |
| 15 |  $CVS | CVS HEALTH Corp | $9.7M | 2.3% | -24% | 51.3 |
| 16 |  $BRKR | BRUKER CORP | $9.2M | 2.2% | -0% | 44.9 |
| 17 |  $GEHC | GE HealthCare Technologies Inc. | $9.0M | 2.1% | +11% | 58.2 |
| 18 |  $ABT | ABBOTT LABORATORIES | $9.0M | 2.1% | NEW | 67 |
| 19 |  $GILD | GILEAD SCIENCES, INC. | $7.4M | 1.8% | -70% | 77.8 |
| 20 |  $LNTH | Lantheus Holdings, Inc. | $7.1M | 1.7% | -1% | 66.9 |
| 21 |  $IQV | IQVIA HOLDINGS INC. | $6.9M | 1.6% | NEW | 59.7 |
| 22 |  $SNDX | Syndax Pharmaceuticals Inc | $6.7M | 1.6% | +13% | 30 |
| 23 |  $BIO | BIO-RAD LABORATORIES, INC. | $6.6M | 1.6% | +0% | 40.3 |
| 24 |  $QGEN | QIAGEN N.V. | $6.5M | 1.5% | NEW | — |
| 25 |  $AVTR | Avantor, Inc. | $5.5M | 1.3% | +0% | 38.4 |
| 26 |  $CNC | CENTENE CORP | $5.3M | 1.3% | -37% | 52.7 |
| 27 |  $TNDM | TANDEM DIABETES CARE INC | $5.1M | 1.2% | +0% | 34.8 |
| 28 |  $PTCT | PTC THERAPEUTICS, INC. | $5.1M | 1.2% | +21% | 80 |
| 29 |  $LH | LABCORP HOLDINGS INC. | $5.1M | 1.2% | -30% | 54.8 |
| 30 |  $ASND | Ascendis Pharma A/S | $4.9M | 1.1% | +31% | 41.5 |
| 31 |  $EW | Edwards Lifesciences Corp | $4.8M | 1.1% | -37% | 67.6 |
| 32 |  $DXCM | DEXCOM INC | $3.5M | 0.8% | -26% | 77.9 |
| 33 |  $CRNX | Crinetics Pharmaceuticals, Inc. | $3.4M | 0.8% | -18% | 26.5 |
| 34 |  $KURA | Kura Oncology, Inc. | $3.3M | 0.8% | -10% | 9.1 |
| 35 |  $HUM | HUMANA INC | $3.3M | 0.8% | NEW | 82 |
| 36 |  $BBIO | BridgeBio Pharma, Inc. | $3.3M | 0.8% | NEW | 31.7 |
| 37 |  $IOVA | IOVANCE BIOTHERAPEUTICS, INC. | $3.2M | 0.8% | NEW | 30.6 |
| 38 |  $DNLI | Denali Therapeutics Inc. | $3.1M | 0.7% | NEW | — |
| 39 |  $ARDX | ARDELYX, INC. | $3.1M | 0.7% | NEW | 35.3 |
| 40 |  $COGT | Cogent Biosciences, Inc. | $3.1M | 0.7% | NEW | — |
| 41 |  $OGN | Organon & Co. | $2.3M | 0.5% | +25% | 55.1 |
| 42 |  $ARWR | ARROWHEAD PHARMACEUTICALS, INC. | $1.9M | 0.4% | NEW | 74.4 |
New Positions (11)
$UNH UNITEDHEALTH GROUP INC$9.9M$ABT ABBOTT LABORATORIES$9.0M$IQV IQVIA HOLDINGS INC.$6.9M$QGEN QIAGEN N.V.$6.5M$HUM HUMANA INC$3.3M$BBIO BridgeBio Pharma, Inc.$3.3M$IOVA IOVANCE BIOTHERAPEUTICS, INC.$3.2M$DNLI Denali Therapeutics Inc.$3.1M$ARDX ARDELYX, INC.$3.1M$COGT Cogent Biosciences, Inc.$3.1M$ARWR ARROWHEAD PHARMACEUTICALS, INC.$1.9M
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for SECTOR GAMMA AS including:
Track SECTOR GAMMA AS's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for SECTOR GAMMA AS and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: SECTOR GAMMA AS
13F Pro is an AI hedge fund tracker and stock research platform. For SECTOR GAMMA AS (SEC CIK: 1475373), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in SECTOR GAMMA AS's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.